A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

62

Citations

14

References

2006

Year

Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Anne Goodwin, Wendy Goodspeed, Marie Kromplewski, Molly E. Fouts, Diane Medina, Steve Y. Cho, Susan L. Cohn,

Clinical Cancer Research

Abstract

ABT-751 is well tolerated in children. The recommended dose for phase 2 trials in solid tumors is 200 mg/m(2)/d administered orally, daily for 7 days every 21 days. This dose is >40% higher than the maximum tolerated dose in adults receiving the same dosing schedule.

References

	Year	Citations

Page 1